Luke Versten, MPH

Senior Associate, New York

Why did you join Deallus?

Despite the promise inherent in the volume of breakthrough therapeutic innovations, challenging questions persist as to how these advances will be tested in research, regulatory, and marketplace contexts. I engage in work that reframes these challenges, raises implications, and enables stakeholders to navigate the complexities of a system defined by constant change. I feel the most rewarded in my work when I can drive product and portfolio level strategic assessments, convey the impact of the latest R&D breakthroughs, and contextualize opportunity across therapeutic landscapes to a variety of stakeholders.

I also chose Deallus because of the people. We’re all very bright on our own but we work well together as a team and that’s fun to be part of. Development is a real priority here and I like being part of that, whether it’s helping to train new joiners or getting coaching from the leadership that helps us improve.

Luke Versten Deallus Senior Associate

Background and experience

  • MPH, Epidemiology of Microbial Diseases, Yale University

  • BS, Biological Sciences, University of Chicago

Therapy area expertise

  • Immuno-oncology

  • Urology

  • NASH

  • Infectious Diseases/Virology

Deallus New York

Life outside of work

I love live music – I went to see Tame Impala recently at MSG. I also love exploring NYC. I like to travel – the next places in the US that are on my list are New England and the Pacific Northwest. I grew up outside Chicago so I am a Bears fan, which was fun last year but… less so this year.

Authored insight

COVID-19 – tracking the fast-moving landscape

As the COVID-19 pandemic continues to impact patients, healthcare systems, and global economic outlooks, we focus on the key considerations and strategies for pharma companies when the data generation for possible therapies is becoming increasingly complex to analyze. There are several COVID-19 treatment and vaccine databases containing an aggregation of publicly-available information from validated sources detailing treatments and vaccines currently in development.

Launch and COVID-19: Pharma’s Dilemma

COVID-19 is throwing a wrench in years’ worth of launch planning, introducing complications and delays into the regulatory process and severely constricting promotional and educational opportunities for new products. How is the pharmaceutical industry responding to these changes in well-laid plans? How are regulatory bodies responding? We consider the potential impact of the pandemic on launch timing and strategy here.

Antimicrobial Resistance

Lack of innovation surrounding the development of new antibiotics has resulted in an alarming situation, given the rising threat of antimicrobial resistance (AMR). As a result, there is no single or straightforward way to combat AMR, nor to galvanize development of novel antibiotics. Although some positive measures have been introduced, further - and larger scale - action is needed. We take a look at what pharma and the larger healthcare industry needs to do in order to combat this looming threat.

People also viewed

Yi Jin

Yi Jin, MSc is an Associate for Deallus based in Shanghai, China.

We are always seeking other like-minded people who are as passionate about their work as we are, have a track record of demonstrating initiative, and are looking for a position where they can achieve their full potential.

Join us!

Join our team
Go to Top